CN1440385A - 用于治疗艾滋病的吡咯衍生物 - Google Patents

用于治疗艾滋病的吡咯衍生物 Download PDF

Info

Publication number
CN1440385A
CN1440385A CN01812290A CN01812290A CN1440385A CN 1440385 A CN1440385 A CN 1440385A CN 01812290 A CN01812290 A CN 01812290A CN 01812290 A CN01812290 A CN 01812290A CN 1440385 A CN1440385 A CN 1440385A
Authority
CN
China
Prior art keywords
methyl
isopropyl
pyridyl
pyrrole
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01812290A
Other languages
English (en)
Chinese (zh)
Inventor
B·W·迪莫克
P·S·约内斯
J·H·梅里特
M·J·帕拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1440385A publication Critical patent/CN1440385A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN01812290A 2000-07-04 2001-04-30 用于治疗艾滋病的吡咯衍生物 Pending CN1440385A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0016453.3A GB0016453D0 (en) 2000-07-04 2000-07-04 Pyrrole derivatives
GB0016453.3 2000-07-04

Publications (1)

Publication Number Publication Date
CN1440385A true CN1440385A (zh) 2003-09-03

Family

ID=9895031

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01812290A Pending CN1440385A (zh) 2000-07-04 2001-04-30 用于治疗艾滋病的吡咯衍生物

Country Status (17)

Country Link
US (1) US6737429B2 (https=)
EP (1) EP1301481A1 (https=)
JP (1) JP2004502674A (https=)
KR (1) KR100549884B1 (https=)
CN (1) CN1440385A (https=)
AR (1) AR028602A1 (https=)
AU (2) AU2001263874B2 (https=)
BR (1) BR0112241A (https=)
CA (1) CA2412270A1 (https=)
EC (1) ECSP014109A (https=)
GB (1) GB0016453D0 (https=)
GT (1) GT200100111A (https=)
MX (1) MXPA02012409A (https=)
PA (1) PA8516201A1 (https=)
PE (1) PE20020269A1 (https=)
UY (1) UY26720A1 (https=)
WO (1) WO2002002524A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081387A1 (zh) * 2009-01-13 2010-07-22 中国人民解放军军事医学科学院毒物药物研究所 N-取代苯基-3-甲烯杂环芳烃-2，5-二甲基吡咯类化合物及其抗hiv/aids的应用
CN101837125A (zh) * 2003-12-26 2010-09-22 萩原正敏 Sr蛋白质的磷酸化控制方法以及以包含sr蛋白质活性控制剂的试剂为有效成分的抗病毒剂

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405849A1 (en) * 2002-10-04 2004-04-07 Corning Incorporated Halogenated styrene compounds and low-absorption-loss polymers obtainable therefrom
WO2006036024A1 (ja) 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited プロトンポンプ阻害薬
TW200628446A (en) * 2004-12-14 2006-08-16 Takeda Pharmaceuticals Co Substituted pyrrole derivative
CA2592909A1 (en) * 2005-01-06 2006-07-13 Pfizer Limited Imidazole derivatives as enzyme reverse transcriptase modulators
AU2006285641A1 (en) 2005-08-30 2007-03-08 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
US20100113421A1 (en) * 2006-10-06 2010-05-06 Williams Theresa M Non-nucleoside reverse transcriptase inhibitors
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2009015180A2 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009050977A1 (en) * 2007-10-16 2009-04-23 Nikon Corporation Illumination optical system, exposure apparatus, and device manufacturing method
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
RS52872B (sr) 2008-08-27 2013-12-31 Takeda Pharmaceutical Company Limited Jedinjenja pirola
GB0823001D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Thiophene,furan and pyrrole derivatives with plant growth regulating properties
WO2021102114A1 (en) * 2019-11-19 2021-05-27 New York Blood Center, Inc. Substituted heterocyclics with therapeutic activity in hiv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644631A (en) * 1969-05-13 1972-02-22 Endo Lab Therapeutic methods utilizing aryl pyrrol-3-yl ketones
US4282242A (en) * 1980-03-07 1981-08-04 Pfizer Inc. Antidiabetic pyrrolecarboxylic acids
US4347186A (en) * 1980-10-20 1982-08-31 Syntex (U.S.A.) Inc. Process for preparing 5-aroyl 1,2-dihydro-3-H pyrrolo[1,2-a]pyrrole-1-carboxylic acids and novel intermediates therein
KR100190730B1 (ko) * 1992-12-17 1999-06-01 디. 제이. 우드, 스피겔 알렌 제이 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸
AU2265495A (en) * 1994-06-06 1996-01-04 Pfizer Inc. Substituted pyrazoles having corticotropin-releasing factor (crf) antagonist activity
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
BR9710352A (pt) * 1996-07-11 1999-08-17 Pfizer Compostos piridilpirrole
DE19963174A1 (de) * 1999-12-27 2001-07-12 Gruenenthal Gmbh Substituierte Pyrrol-Mannichbasen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101837125A (zh) * 2003-12-26 2010-09-22 萩原正敏 Sr蛋白质的磷酸化控制方法以及以包含sr蛋白质活性控制剂的试剂为有效成分的抗病毒剂
WO2010081387A1 (zh) * 2009-01-13 2010-07-22 中国人民解放军军事医学科学院毒物药物研究所 N-取代苯基-3-甲烯杂环芳烃-2，5-二甲基吡咯类化合物及其抗hiv/aids的应用

Also Published As

Publication number Publication date
KR100549884B1 (ko) 2006-02-06
WO2002002524A1 (en) 2002-01-10
JP2004502674A (ja) 2004-01-29
CA2412270A1 (en) 2002-01-10
AU2001263874B2 (en) 2006-10-19
BR0112241A (pt) 2003-06-24
AU6387401A (en) 2002-01-14
KR20030014321A (ko) 2003-02-15
ECSP014109A (es) 2002-02-25
GT200100111A (es) 2002-03-18
EP1301481A1 (en) 2003-04-16
PA8516201A1 (es) 2002-07-30
GB0016453D0 (en) 2000-08-23
PE20020269A1 (es) 2002-04-08
MXPA02012409A (es) 2003-04-25
US20020032221A1 (en) 2002-03-14
AR028602A1 (es) 2003-05-14
UY26720A1 (es) 2001-11-30
US6737429B2 (en) 2004-05-18

Similar Documents

Publication Publication Date Title
CN1167680C (zh) 稠环化合物及其药物用途
CN1184214C (zh) α－酰基和α－杂原子取代的苯乙酰胺葡糖激酶活化剂
CN1191239C (zh) 用于治疗病毒性疾病的吡唑衍生物
CN1440385A (zh) 用于治疗艾滋病的吡咯衍生物
CN1653047A (zh) 抗炎症药物单环芳酰吡啶酮
CN1378544A (zh) 取代的唑系化合物
CN1665789A (zh) 二氨基嘧啶酰胺衍生物
CN1668603A (zh) 用作pde4抑制剂的哒嗪－3(2h)－酮衍生物
CN1249052C (zh) 作为hiv逆转录酶抑制剂的吡唑衍生物
CN1214339A (zh) 吡唑衍生物、其制备方法和在药物中的应用
CN1918119A (zh) 双环酯类衍生物
CN1441783A (zh) 含二氰基吡啶衍生物的药物
CN1585749A (zh) 类大麻苷受体配体
CN1933834A (zh) 吲唑甲酰胺衍生物在制备用于治疗和预防疟疾的药物中的用途
CN1160402A (zh) 用作pnp抑制剂的嘌呤和鸟嘌呤化合物
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1387517A (zh) 作为环加氧酶－2抑制剂的5－芳基－1h－1,2,4－三唑化合物及含有它们的药物组合物
CN1910157A (zh) 对受体cbi有亲和性的n′－(1,5－二苯基－1h－吡唑－3－基)磺酰胺衍生物
CN1210257C (zh) 取代的芳香环化合物及其制备方法和用途
CN1859914A (zh) 苯基吡咯烷醚速激肽受体拮抗剂
CN1473156A (zh) 嘧啶衍生物及其作为神经肽y受体配体的用途
HK1042691A1 (zh) 磺酰胺异羟肟酸脂
CN87107226A (zh) 内酰胺衍生物及其制备
CN1852907A (zh) 2－氨基－5－苯甲酰基噻唑npy拮抗剂
CN1708478A (zh) 对(磺酰基)芳基和杂芳基类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication